DOI: 10.3724/SP.J.1008.2010.00904

Academic Journal of Second Military Medical University (第二军医大学学报) 2010/30:8 PP.904-906

Non-elevated cardiovascular risk in patients with primary biliary cirrhosis and hypercholesterolemia

Primary biliary cirrhosis (PBC) is an autoimmune disease with unknown causes. Most PBC patients have abnormal lipid metabolism characterized by hypercholesterolemia. Paradoxically, clinical observations and pre-experimental studies showed that the risk of hyperlipidemia associated cardiovascular event and the mortality of PBC patients were not increased. In this review we summarize the possible reasons and the underlying mechanisms.

Key words:primary biliary cirrhosis,hypercholesterolemia,cardiovascular risk

ReleaseDate:2014-07-21 15:25:19

Funds:National High-tech R&D Program(“863” Program, 2006AA02Z496) and Foundation for Leading Scientists of Science and Technology Commission of Shanghai Municipality (07XD14013).

[1] Kaplan M M,Gershwin M E.Primary biliary cirrhosis[J].N Engl J Med,2005,353:1261-1273.

[2] Longo M,Crosignani A,Battezzati P M,Squarcia Giussani C,Invernizzi P,Zuin M,et al.Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis[J].Gut,2002,51:265-269.

[3] Crippin J S,Lindor K D,Jorgensen R,Kottke B A,Harrison J M,Murtaugh P A,et al.Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk[J]?Hepatology,1992,15:858-862.

[4] Allocca M,Crosignani A,Gritti A,Ghilardi G,Gobatti D,Caruso D,et al.Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis[J].Gut,2006,55:1795-800.

[5] Sorokin A,Brown J L,Thompson P D.Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review[J].Atherosclerosis,2007,194:293-299.

[6] Solaymani-Dodaran M,Aithal G P,Card T,West J.Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study[J].Am J Gastroenterol,2008,103:2784-2788.

[7] Jahn C E,Schaefer E J,Taam L A,Hoofnagle J H,Lindgren F T,Albers J J,et al.Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification[J]. Gastroenterology,1985,89:1266-1278.

[8] Fellin R,Manzato E,Zotti S,Baggio G,Briani G,Rugge M.Lipoprotein-X and diagnosis of cholestasis: comparison with other biochemical parameters and liver biopsy[J].Clin Chim Acta,1978,85:41-47.

[9] Soros P,Bottcher J,Maschek H,Selberg O,Müller M J.Lipoprotein-X in patients with cirrhosis: its relationship to cholestasis and hypercholesterolemia[J].Hepatology,1998,28:1199-1205.

[10] Foley K F,Silveira M G,Hornseth J M,Lindor K D,McConnell J P.A patient with primary biliary cirrhosis and elevated LDL cholesterol[J].Clin Chem,2009,55:187-191.

[11] Su T C,Hwang J J,Kao J H.Hypercholesterolemia in primary biliary cirrhosis[J].N Engl J Med,2007,357: 1561-1562.

[12] Fei H,Maeda S,Kirii H,Fujigaki S,Maekawa N,Fujii H,et al.Evaluation of two different homogeneous assays for LDL-cholesterol in lipoprotein-X-positive serum[J].Clin Chem,2000,46:1351-1356.

[13] Herzum I,Giehl C,Soufi M,Junclas H,Wahl H G.Interference in a homogeneous assay for low-density lipoprotein cholesterol by lipoprotein X[J].Clin Chem Lab Med,2007,45:667-671.

[14] Koga S,Miyata Y,Ibayashi H.Plasma lipoproteins and apoproteins in primary biliary cirrhosis[J].Hepatology,1985,5:286-292.

[15] Seidel D,Alaupovic P,Furman R H.A lipoprotein characterizing obstructive jaundice. Ⅰ. Method for quantitative separation and identification of lipoproteins in jaundiced subjects[J].J Clin Invest,1969,48:1211-1223.

[16] Zhu X,Herzenberg A M,Eskandarian M,Maguire G F,Scholey J W,Connelly P W,et al.A novel in vivo lecithin-cholesterol acyltransferase (LCAT)-deficient mouse expressing predominantly LpX is associated with spontaneous glomerulopathy[J].Am J Pathol,2004,165:1269-1278.

[17] Chang P Y,Lu S C,Su T C,Chou S F,Huang W H,Morrisett J D,et al.Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation[J].J Lipid Res,2004,45:2116-2122.

[18] Mayer M.Association of serum bilirubin concentration with risk of coronary artery disease[J].Clin Chem,2000,46:1723-1727.

[19] Hopkins P N,Wu L L,Hunt S C,James B C,Vincent G M,Williams R R.Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease[J].Arterioscler Thromb Vasc Biol,1996,16:250-255.

[20] Schwertner H A,Jackson W G,Tolan G.Association of low serum concentration of bilirubin with increased risk of coronary artery disease[J].Clin Chem,1994,40:18-23.

[21] Dudnik L B,Azyzova O A,Solovyova N P,Savchenkova A P,Pokrovskaya M A.Primary biliary cirrhosis and coronary atherosclerosis: protective antioxidant effect of bilirubin[J].Bull Exp Biol Med,2008,145:18-22.

[22] Goldstein B J,Scalia R G,Ma X L.Protective vascular and myocardial effects of adiponectin[J].Nat Clin Pract Cardiovasc Med,2009,6:27-35.

[23] Okamoto Y,Kihara S,Ouchi N,Nishida M,Arita Y,Kumada M,et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice[J]. Circulation,2002,106:2767-2770.

[24] Ouchi N,Kihara S,Arita Y,Maeda K,Kuriyama H,Okamoto Y,et al.Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin[J].Circulation,1999,100:2473-2476.

[25] Floreani A,Variola A,Niro G,Premoli A,Baldo V,Gambino R,et al.Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis[J].Am J Gastroenterol,2008,103:1959-1965.

[26] Stojakovic T,Claudel T,Putz-Bankuti C,Fauler G,Scharnagl H,Wagner M,et al.Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment[J]. Atherosclerosis,2010,209:178-183.

[27] Balmer M L,Dufour J F.Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated[J].Swiss Med Wkly,2008,138(29-30):415-419.